Adriamycin prices near Virginia Beach, VA
Lowest: $129.00 Highest: $156.30
What is Adriamycin?
USES: Doxorubicin is an anthracycline type of chemotherapy that is used to treat several different types of cancer. Doxorubicin works by slowing or stopping the growth of cancer cells.
How to take Adriamycin
HOW TO USE: Read the Patient Information Leaflet if available from your pharmacist before you start receiving doxorubicin and each time you get an infusion. If you have any questions, ask your doctor or pharmacist. This medication is given by injection into a vein by a health care professional. The dosage is based on your medical condition, body size, and response to therapy. If this medication touches your skin, immediately and completely wash the skin with soap and water. If this medication gets in your eye, open the eyelids and flush with plenty of water for 15 minutes. Seek immediate medical attention. Caregivers should take precautions (e.g., wear gloves) to prevent contact with the patient's urine or other body fluid for at least 5 days after treatment. Consult your pharmacist. Unless your doctor instructs you otherwise, drink plenty of cool fluids during treatment with this medication. This helps move the drug quickly through your body and helps reduce some of the side effects.
WARNING: This medication must be given slowly into a vein only. It is very important not to inject this medication into a muscle or beneath the skin. If this medication accidentally leaks into surrounding tissue, the skin/muscle may be severely damaged. Notify your doctor right away if redness, blistering, sores, pain, or swelling occur at or near the injection site. Doxorubicin may cause heart problems, including possibly fatal heart failure. Heart problems may occur during doxorubicin therapy or months to years after receiving this medication. Your risk of developing heart problems depends on your dose, medical history (including previous heart disease, radiation therapy in the chest area), and previous use of this and other drugs (including daunorubicin and cyclophosphamide). Children are at higher risk and should be monitored later in life for delayed heart problems. See also Side Effects section. Very rarely, people with cancer who are treated with this type of medication have developed other cancers (e.g., secondary leukemia). The risk is greater if you are over age 50 or have received certain types of chemotherapy or radiation therapy. Consult your doctor for more details. This medication may cause certain severe (rarely fatal) blood disorders (bone marrow suppression leading to low red blood cells/white blood cells /platelets). This can lower your body's ability to fight infection and stop bleeding. Tell your doctor right away if you develop any signs of infection (e.g., fever, chills, persistent sore throat), unusual tiredness, or easy bleeding/bruising. Your doctor will closely monitor you while you are being treated with this medication. Different types of this medication work in different ways. Do not switch types of this medication without your doctor's permission.
What if I miss a dose of Adriamycin?
MISSED DOSE: For the best possible benefit, it is important to receive each scheduled dose of this medication as directed. If you miss a dose, contact your doctor or pharmacist right away to establish a new dosing schedule.
STORAGE: Consult the product instructions and your pharmacist for storage details. Keep all medications away from children and pets. Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Side Effects of Adriamycin
SIDE EFFECTS: See also Warning section. Nausea, vomiting, diarrhea, and loss of appetite may occur. Nausea and vomiting can be severe. In some cases, drug therapy may be needed to prevent or relieve nausea and vomiting. Not eating before your treatment may help relieve vomiting. Changes in diet and lifestyle, such as eating several small meals and limiting activity, may help lessen some of these effects. If any of these effects continue or worsen, notify your doctor or pharmacist. Doxorubicin may give a reddish color to your urine, tears, and sweat. This effect may start in the first hours after treatment and may last up to several days. This is a normal effect of the drug and should not be mistaken for blood in your urine. Temporary hair loss may occur. Normal hair growth should return after treatment has ended. Nail changes (including fungal infections in the nail beds) may rarely occur. Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects. Tell your doctor right away if you have any serious side effects, including: symptoms of heart failure (such as shortness of breath, swelling ankles/feet, unusual tiredness, unusual/sudden weight gain), redness/flushing of face, eye redness/itching, cough/hoarseness, persistent diarrhea, joint pain, pain in the lower back/side/stomach/abdomen, painful/difficult urination, stopped/missed menstrual periods, black/tarry stools, bloody mucus or discharge in stools, fast/irregular heartbeat, dizziness, decreased urination. Painful sores on the lips, mouth and throat may occur. To decrease the risk, limit hot foods and drinks, brush your teeth carefully, avoid using mouthwash that contains alcohol, and rinse your mouth frequently with cool water. Get medical help right away if you have any very serious side effects, including: chest pain. Within days to weeks after doxorubicin treatment, a serious skin reaction that looks likes a severe sunburn (radiation recall) may develop on any area of skin that has been previously treated with radiation. Also, doxorubicin may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you have skin redness, pain, tenderness, swelling, peeling, blisters, or if you get sunburned. Your doctor may prescribe medication to help your skin heal faster and reduce the swelling. In children, radiation recall may occur in the lungs. Tell the doctor right away if you notice wheezing or trouble breathing in the child. A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing. This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist. In the US - Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch. In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Interactions with Adriamycin
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval. Some products that may interact with this drug include: digoxin, progesterone, streptozocin, stavudine, trastuzumab, zidovudine. Other medications can affect the removal of doxorubicin from your body, which may affect how doxorubicin works. Examples include azole antifungals (such as ketoconazole), calcium channel blockers (e.g., verapamil, nifedipine), rifamycins (such as rifabutin), St. John's wort, drugs used to treat seizures (such as carbamazepine, phenytoin, phenobarbital, primidone), among others. Avoid eating foods or products containing turmeric (curcumin) while taking doxorubicin. It may decrease doxorubicin's effects. Consult your doctor or pharmacist for more details.
PRECAUTIONS: See also Side Effects section. Before using doxorubicin, tell your doctor or pharmacist if you are allergic to it; or to lincomycin; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details. Before using this medication, tell your doctor or pharmacist your medical history, especially of: a current infection, low blood cell counts (e.g., anemia, neutropenia, thrombocytopenia), gout, heart problems (e.g., recent heart attack, heart failure, irregular heartbeat), a history of receiving any anthracycline-type drug (e.g., doxorubicin, idarubicin, daunorubicin, mitoxantrone), kidney problems, liver disease, severe mouth sores (stomatitis), radiation treatment (especially to the chest area). Do not have immunizations/vaccinations without the consent of your doctor, and avoid contact with people who have recently received oral polio vaccine. To lower the chance of getting cut, bruised, or injured, use caution with sharp objects like safety razors and nail cutters, and avoid activities such as contact sports. Use a soft-bristle toothbrush to lower the risk of bleeding gums. Wash your hands well to prevent the spread of infections. Caution is advised when using this drug in children because they may be more sensitive to the effects of the drug, especially to radiation recall in the lungs, heart problems, or another cancer later on in life. Doxorubicin, in combination with other chemotherapies, may also slow the growth of children before puberty. This medication may lower sperm count or may cause abnormal sperm to form, possibly causing infertility or birth defects. Consult your doctor for more details. This medication can affect menstruation in females and cause premature menopause. Consult your doctor or pharmacist for details. Tell your doctor if you are pregnant or plan to become pregnant. Your doctor will give you a pregnancy test before starting treatment. You should not become pregnant while using doxorubicin. Doxorubicin may harm an unborn baby. Women and men should ask about reliable forms of birth control to use during treatment with this medication and for 6 months after stopping treatment. If you or your female partner becomes pregnant, talk to your doctor right away about the risks and benefits of this medication. This medication passes into breast milk. Because of the potential risk to the infant, breast-feeding while using this drug is not recommended. Consult your doctor before breast-feeding.
Conditions Commonly Treated by Adriamycin
Prescription prices may vary from pharmacy to pharmacy and are subject to change. The pricing estimates given are based on the most recent information available and may change based on when you actually fill your prescription at the pharmacy. The day supply is based upon the average dispensing patterns or the specific drug and strength. The Program, as well as the prices and the list of covered drugs, can be modified at any time without notice.
Blog Posts Related to Adriamycin
Streamlining the process of bringing biosimilars to market is one of the keys to facilitating innovation and reducing healthcare costs, according to US Food and Drug Administration (FDA) Commissioner Scott Gottlieb.
Speaking at the Brookings Institution on the release of the FDA’s...
Fulphila (pegfilgrastim-jmdb) is the first biosimilar to Neulasta (pegfilgrastim) to gain approval from the US Food and Drug Administration (FDA). The Mylan GmbH medicine was approved as a treatment to reduce the risk of infection as suggested by febrile neutropenia (fever caused by a lack of...
Lynparza (olaparib tablets) is the first poly (ADP-ribose) polymerase (PARP) inhibitor indicated for the treatment of patients with breast cancer whose tumors have a specific inherited genetic mutation. Lynparza is already approved in the United States as a treatment for a number of other cancers,...
More than four in ten (42 percent) of cancer cases in the United States are linked to risk factors associated with cancer, such as smoking, obesity, poor diet, ultraviolet radiation and physical inactivity, according to a new study conducted by the American Cancer Society. The results of the...
Overweight or obese Americans are at a higher risk of developing cancer, according to the latest Vital Signs report from the Centers for Disease Control and Prevention (CDC). At least 13 different types of cancer are associated with obesity, yet figures suggest more than half of Americans are...
Patients with HER2 breast cancer will have a new treatment option available later this year, following the US Food and Drug Administration's (FDA) approval of the first extended adjuvant treatment for the condition. Nerlynx (neratinib), a kinase inhibitor from Puma Biotechnology, was granted FDA...
A Phase III OlympiAD trial of Lynparza (olaparib) tablets for treating patients with HER2-negative gBRCA-mutated metastatic breast cancer has yielded positive results with a "statistically-significant and clinically-meaningful improvement in progression-free survival". Pharmaceutical firm...
The US Food and Drug Administration (FDA) has approved Adcetris (brentuximab vedotin) as a treatment for certain adult patients with classical Hodgkin lymphoma (cHL). Under the latest approval, the Seattle Genetics drug is indicated for use in combination with chemotherapy as a treatment for...
The US Food and Drug Administration (FDA) has issued a statement clarifying its position on Keytruda (pembrolizumab) after scientists monitoring studies of the drug found an excess of deaths among patients given the drug in combination with certain other medicines.
Currently, Keytruda is...
The US Food & Drug Administration's (FDA) decision to approve a medication to treat patients whose cancer has a specific genetic feature, or biomarker, has been hailed as an "important first" in the fight against the disease. Keytruda (pembrolizumab) is a monoclonal antibody already in use to...
Cancer medication Blincyto (blinatumomab) has received accelerated approval as a treatment to reduce the risk of relapse in certain patients with B-cell precursor acute lymphoblastic leukemia (ALL). Under the latest US Food and Drug Administration (FDA) approval, Blincyto is indicated for adults...
Over the course of 2017, the number of approvals granted by the US Food and Drug Administration (FDA) reached a 21-year high. More than 1,000 generic drugs were approved by the agency, according to FDA Commissioner Scott Gottlieb, MD, while first-time generic drug approvals numbered 74. Novel drug...
Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) have a new targeted treatment option, following the US Food and Drug Administration's (FDA) approval of Besponsa (inotuzumab ozogamicin). The drug, developed by Pfizer, was granted Priority Review,...
Pfizer's acute myeloid leukemia (AML) medicine Mylotarg (gemtuzumab, ozogamicin) has been granted Orphan Drug Designation by the US Food and Drug Administration (FDA). The drug is indicated for the treatment of adults with newly diagnosed AML whose tumors express the CD33 antigen (CD33-positive...
Vyxeos (daunorubicin and cytarabine) has been approved by the US Food and Drug Administration (FDA). It is the first treatment approved for patients with certain types of high-risk acute myeloid leukemia (AML). The drug, developed by Jazz Pharmaceuticals, is a fixed combination of two chemotherapy...
Similar Drugs To Adriamycin & Other Anthracyclines